Will Teva's Deal With AstraZeneca Over Nexium Patents Erode Ranbaxy's Marketing Exclusivity In 2014?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Teva's patent dispute settlement with AstraZeneca for a delayed launch of generic copies of the blockbuster heartburn drug brand Nexium (esomeprazole) led to enormous confusion and panic among Indian stock market investors regarding the status of Ranbaxy's 180-day sole marketing exclusivity for the drug starting May 2014
You may also be interested in...
Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
Ranbaxy Reports Corrections At Dewas Plant To U.S. FDA; Hopes Import Restrictions Will Be Lifted Soon
MUMBAI - Part of Ranbaxy's troubles with its manufacturing units in India may be coming to an end in the next few months; the company has filed an exhaustive report with the U.S. FDA on corrections made at its manufacturing facilities at Dewas